5 Amino 1MQ and Its Role in Metabolic Regulation

5-Amino-1MQ (often written 5-amino-1-methylquinolinium) is a small-molecule compound that blocks an enzyme called NNMT, and in doing so it reshapes several metabolic pathways tied to fat storage, blood sugar regulation, and muscle function. In preclinical animal studies, it has reduced body fat, improved insulin sensitivity, boosted grip strength in aged mice, and even altered the composition of gut bacteria. All of this research remains at the animal-model stage, with no completed human clinical trials, but the breadth of metabolic effects observed so far has made it one of the more closely watched experimental compounds in obesity and aging research.

The Enzyme It Blocks

To understand what 5-amino-1MQ does, you need to know a little about the enzyme it targets. NNMT (nicotinamide N-methyltransferase) is found primarily in fat tissue and the liver. Its job is to take nicotinamide, a form of vitamin B3 that cells use to make NAD+, and chemically modify it so it can no longer be recycled into NAD+. NAD+ is a molecule involved in hundreds of metabolic reactions, from burning fuel for energy to repairing DNA. When NNMT is overactive, it drains the pool of nicotinamide available to make NAD+, and it simultaneously produces a byproduct that raises homocysteine levels, a compound linked to cardiovascular risk.¹

People with type 2 diabetes tend to have roughly twice the NNMT activity in their fat tissue compared to people with normal blood sugar, and the more NNMT activity present, the worse their insulin sensitivity tends to be.² That correlation is what made NNMT an attractive drug target: if the enzyme is overactive in metabolic disease, inhibiting it might restore some balance.

5-Amino-1MQ was designed to be highly selective. In testing against related enzymes that also use the same methyl-donor molecule, it did not interfere with them, and it left the NAD+ recycling pathway itself intact.³ That specificity matters because a less selective compound could disrupt essential methylation reactions throughout the body.

Fat Loss in Obese Mice

The most widely cited metabolic effect of 5-amino-1MQ is its impact on body fat. In diet-induced obese mice, treatment with the compound significantly reduced body weight and white adipose (fat) tissue mass, shrank the size of individual fat cells, and lowered plasma cholesterol. The animals kept eating the same amount of food throughout the experiment, so the weight loss was not driven by appetite suppression.³

A follow-up study combined 5-amino-1MQ treatment with a switch from a high-fat diet to a normal low-fat diet, mimicking what happens when someone starts eating better. By the end of the study, the treated mice had a fat mass indistinguishable from mice that had never been obese at all. Vehicle-treated mice that made the same dietary switch still carried more fat than the lean controls.⁴ The implication is that NNMT inhibition did not just slow fat gain but actively promoted fat loss beyond what dietary change alone could accomplish.

A separate dose-response study confirmed these findings, showing that higher doses of 5-amino-1MQ produced progressively greater reductions in body weight and fat mass in obese mice.⁵ The dose-dependent pattern strengthens the case that the effect is genuinely tied to NNMT inhibition rather than some off-target quirk of the molecule.

Blood Sugar and Insulin Sensitivity

Fat loss is only part of the metabolic picture. Several of these same studies measured how well the animals handled glucose and responded to insulin, and the results consistently showed improvement. In the dose-response experiment, 5-amino-1MQ treatment improved oral glucose tolerance, increased insulin sensitivity, and suppressed the abnormally high insulin levels that obese mice typically develop.⁵

A review of the broader NNMT-inhibition literature found a consistent pattern: whether NNMT was knocked down genetically or inhibited by a small molecule like 5-amino-1MQ, the result was increased energy expenditure, normalized fasting blood glucose, and improved glucose tolerance.⁶ These effects likely stem from the same underlying mechanism: by blocking NNMT, more nicotinamide is available to replenish NAD+, which in turn fuels the metabolic reactions cells use to burn glucose and fatty acids for energy.

The human correlation data are suggestive as well. In people with insulin resistance, plasma levels of 1-methylnicotinamide (the product NNMT creates) and adipose NNMT gene expression both track inversely with insulin sensitivity.² That does not prove that blocking NNMT in humans would fix insulin resistance, but it does show the association is there across species.

Muscle Strength and Exercise Performance in Aged Mice

One of the more surprising lines of research involves 5-amino-1MQ’s effects on aging muscle. A 2024 study tested the compound in aged mice, both sedentary and exercising, and found that treated sedentary mice gained roughly 40% more grip strength than untreated sedentary mice. That increase was actually larger than what exercise alone produced, which was about a 20% improvement. When the compound and exercise were combined, the gains stacked: treated exercising mice showed around a 60% grip strength increase over untreated sedentary controls.⁷

The study also looked at what was happening inside the muscle fibers. Treated sedentary mice had over 30% less intramyocellular lipid (fat stored inside muscle cells) compared to untreated sedentary mice, bringing their levels close to those seen in the exercising groups. This reduction in muscle fat was accompanied by increased levels of carnitine, a molecule muscles need to shuttle fatty acids into mitochondria for burning. In other words, the compound appeared to push aged muscle toward using fat for fuel more efficiently, a shift that typically only happens with regular exercise.⁷

The same research group also tracked running distances in exercising mice over about two months. Mice that exercised without treatment initially ran farther each day but then tapered off, likely from accumulated fatigue. When 5-amino-1MQ was added to the exercise routine, daily running distances increased and the taper was much less pronounced, suggesting the compound helped with recovery between bouts of vigorous activity. For anyone interested in sarcopenia (the age-related loss of muscle mass and strength), these findings are intriguing, though they remain confined to mice for now.

Shifts in Gut Bacteria

A less expected finding from the combined diet-and-treatment study was that 5-amino-1MQ reshaped the gut microbiome of obese mice in a way that neither dietary change nor NNMT inhibition alone fully explained. Treated mice switched from a high-fat to a low-fat diet developed a microbial profile that was statistically distinct from every other group in the study, including untreated mice that made the same dietary switch.⁴

Two bacterial genera stood out. Lactobacillus, a group commonly associated with metabolic health, was dramatically higher in the treated group compared to all other groups. Meanwhile, Erysipelatoclostridium, a genus that has been linked to higher body weight, was lower in treated mice. Both of these genera have established ties to body weight and metabolic regulation in the broader microbiome literature.⁴

Whether the microbiome shift is a cause of the metabolic improvements or a downstream consequence is not yet clear. Fat loss and altered nutrient absorption could plausibly change which bacteria thrive, so the direction of causality is an open question. Still, the finding adds another dimension to the compound’s metabolic footprint and suggests that NNMT inhibition may influence metabolism through routes beyond direct changes to fat and muscle.

Connections to Heart Disease and Cancer

Because NNMT sits at the intersection of NAD+ metabolism, methylation, and homocysteine production, its relevance extends beyond obesity and diabetes. Elevated homocysteine is a recognized risk factor for cardiovascular disease, and NNMT’s role in generating it has drawn attention from cardiologists. Preclinical studies using NNMT inhibitors and RNA-based knockdown strategies have shown reduced atherosclerosis and improved cardiac function in animal models of metabolic disease.⁸

NNMT is also overexpressed in several types of cancer, where it appears to help tumor cells rewire their metabolism and resist certain treatments. A 2025 review described NNMT’s abnormal activation as something that disrupts the normal balance between energy metabolism and methylation in cells, fueling diseases including not just diabetes and obesity but also fibrosis and cancer.⁹ Whether 5-amino-1MQ specifically would be useful in oncology settings is a separate question from whether it helps with metabolic regulation, but the overlap in the target enzyme means findings in one area inform the other.

How the Compound Moves Through the Body

For any drug candidate, getting absorbed and reaching its target tissue matters as much as what it does when it arrives. A pharmacokinetic study in rats measured how 5-amino-1MQ behaves after both intravenous and oral dosing. The compound showed reasonable oral bioavailability of about 38%, meaning a little over a third of an oral dose reached the bloodstream intact. Its half-life after oral administration was roughly seven hours, and peak plasma concentrations were substantial.¹⁰

The early structural work on 5-amino-1MQ had already suggested good membrane permeability. The methylquinolinium scaffold the compound is built on was specifically chosen because it crosses cell membranes efficiently through both passive diffusion and active transport, which means it can reach intracellular NNMT rather than being stuck outside the cell.³ These are encouraging properties for a drug candidate, though pharmacokinetics in rats do not always predict what happens in humans.

Safety and Selectivity So Far

The preclinical safety data on 5-amino-1MQ, while limited, has been reassuring in certain respects. In the original obesity study, systemic administration of the compound to mice over ten days did not produce any observable adverse effects, and it did not suppress food intake, ruling out a mechanism that could cause unhealthy weight loss through appetite disruption.³ The compound’s selectivity for NNMT over related methyltransferases and NAD+ salvage enzymes is a meaningful safety feature, since hitting those off-target pathways could cause widespread metabolic disruption.

That said, “no observable adverse effects” in a short mouse study is a low bar for declaring something safe. Toxicology studies, long-term dosing data, organ function panels, and eventually human phase I trials are all steps that remain ahead. The compound is currently sold by some research chemical suppliers and peptide vendors, meaning some people are already self-experimenting with it. Without human safety data, doing so carries risks that cannot be quantified from the existing evidence. We do not know whether the compound interacts with common medications, whether chronic dosing causes tissue accumulation, or whether its metabolic effects behave the same way in people as they do in mice.

Why NNMT Inhibition Is Not the Same as Taking NAD+ Precursors

A common point of confusion is how 5-amino-1MQ relates to NAD+ boosting supplements like NMN and NR (nicotinamide riboside), which have received heavy consumer interest in the longevity space. Both strategies aim to raise NAD+ levels, but they work from opposite ends. NMN and NR supply extra raw material for the cell to build NAD+. NNMT inhibition, by contrast, prevents the cell from draining its existing supply of nicotinamide before it can be recycled into NAD+. Think of it as plugging a leak versus turning up the faucet.

The distinction has practical implications. NNMT inhibition also reduces the production of 1-methylnicotinamide and, downstream, homocysteine. NAD+ precursor supplements do not do that. NNMT inhibition also directly affects fat tissue metabolism, energy expenditure, and the methylation balance in cells in ways that simply flooding the system with more nicotinamide precursors would not replicate. Whether one approach is better than the other, or whether they could complement each other, is a genuinely open research question. Preclinical work validates NNMT as a therapeutic target for metabolic syndrome and its associated diseases,¹ but no study has directly compared 5-amino-1MQ head-to-head with NAD+ precursor supplementation.

For anyone following the NAD+ research space, NNMT inhibitors represent a fundamentally different therapeutic angle. Rather than trying to overwhelm a broken system with extra substrate, they aim to fix the part of the system that is wasting substrate in the first place. Whether that turns out to matter more in practice is something only human trials will answer.